Special Protocol Assessments Get Special Focus In Antibiotic Guidance

FDA’s final guidance on use of non-inferiority studies to support antibacterial drug approval is little changed from a 2007 draft version, but it provides further clarity for sponsors operating under a special protocol assessment.